JNJ Research Update — June 20, 2026
Updated Thesis
Johnson & Johnson is a leading global healthcare company focused on innovative medicine and MedTech following the Kenvue consumer spin-off. It benefits from a durable competitive moat with strong market positions in pharmaceuticals and medical devices, supported by a long-tenured management team and disciplined capital allocation. However, the stock is currently very expensive, trading approximately 21% above its fair value of $181.44 with a P/E of 26.34 and P/FCF of 30.89, reflecting high expectations despite recent earnings pressure with a 52.4% decline in earnings in the most recent quarter.
The investment grade as of this refresh is D — solid business quality. High-tier business, D-tier valuation with 20.6% downside to $181.44 fair value
Key Metrics at a Glance
- Revenue growth: +9.9% year over year
- Net margin: 21.8%
- Forward P/E: 26.3x
- Fair value upside: -20.6% to our estimate of $181
Current price: $228.39
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Johnson & Johnson remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full JNJ research →](/stocks/JNJ)